🔎 Trials Near Me

Home › Cancro alla prostata › Oregon

Studi clinici su Cancro alla prostata nello stato di Oregon

38 studi su Cancro alla prostata cercano partecipanti presso sedi nello stato di Oregon.

Città nello stato di Oregon

Testo ufficiale dello studio (inglese)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Oregon Health & Science University (OHSU), Portland
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 2 ott 2026 · NCT07200830

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • e altri 7
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Oregon Health and Science University, Portland
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06632977

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • e altri 1
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT03866382

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

  • Oregon Health And Science University, Portland
In reclutamentoFase 1
Età 18 e oltre · Uomini · Aggiornato il 28 set 2026 · NCT06095089

Precision-Based Genomics in Prostate Cancer

  • Oregon Health Sciences University, Portland
In reclutamentoStudio osservazionale
Età da 18 a 120 · Uomini · Aggiornato il 28 set 2026 · NCT04706663

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

  • Providence Portland Medical Center, Portland
In reclutamentoFase 1
Età 18 e oltre · Uomini · Aggiornato il 24 set 2026 · NCT07543055

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  • Oregon Urology Institute, Springfield
In reclutamentoFase 2/3
Età da 18 a 100 · Uomini · Aggiornato il 22 set 2026 · NCT06780670

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  • Oregon Oncology Specialists, Salem
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 22 set 2026 · NCT07213674

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  • Research Site, Springfield
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 18 set 2026 · NCT06952803

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

  • VA Portland Health Care System, Portland, OR, Portland
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 17 set 2026 · NCT05011383

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

  • VA Portland Health Care System, Portland, OR, Portland
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 17 set 2026 · NCT04038502

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  • VA Portland Health Care System ( Site 0038), Portland
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 17 set 2026 · NCT06925737

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  • Oregon Urology, Springfield
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 11 set 2026 · NCT06056830

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • Providence Portland Medical Center, Portland
  • e altri 2
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 10 set 2026 · NCT05946213

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

  • Oregon Health & Science University, Portland
In reclutamento
Età 18 e oltre · Uomini · Aggiornato il 1 set 2026 · NCT05710380

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

  • Oregon Health & Science University, Portland
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 31 ago 2026 · NCT05726292

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

  • Research Site, Portland
In reclutamentoFase 1/2
Età da 18 a 99 · Uomini · Aggiornato il 27 ago 2026 · NCT07590934

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  • Research Site, Portland
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 26 ago 2026 · NCT07611110

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • Bay Area Hospital, Coos Bay
  • e altri 5
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 19 ago 2026 · NCT04423211

FOG-001 in Locally Advanced or Metastatic Solid Tumors

  • Oregon Health and Science University, Portland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05919264

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • Bay Area Hospital, Coos Bay
  • e altri 8
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 14 lug 2026 · NCT06592924

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

  • Oregon Health & Science University, Portland
In reclutamentoFase 1/2
Età 18 e oltre · Uomini · Aggiornato il 25 giu 2026 · NCT06457919

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

  • VA Portland Health Care System, Portland
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 15 giu 2026 · NCT05422911

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

  • Oregon Health & Science University Hospital, Portland
In reclutamentoStudio osservazionale
Età 21 e oltre · Uomini · Aggiornato il 22 mag 2026 · NCT03151629

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

  • OHSU Knight Cancer Institute, Portland
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età 40 e oltre · Uomini · Aggiornato il 15 mag 2026 · NCT04472338

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Research Site, Portland
In reclutamentoFase 1
Età 18 e oltre · Uomini · Aggiornato il 12 mag 2026 · NCT06879041

Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE

  • OHSU Knight Cancer Institute, Portland
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 mag 2026 · NCT06011499

GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer

  • OHSU Knight Cancer Institute, Portland
In reclutamento
Età 65 e oltre · Uomini · Aggiornato il 6 mag 2026 · NCT07504835

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

  • Saint Alphonsus Medical Center-Baker City, Baker City
  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • e altri 9
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 29 gen 2026 · NCT05806515

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 22 gen 2026 · NCT06470243

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Oregon Health Sciences University, Portland
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età 40 e oltre · Tutti i sessi · Aggiornato il 20 gen 2026 · NCT05366881

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Portland
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774

EMBRACE: Exercising Together

  • OHSU Knight Cancer Institute, Portland
In reclutamentoFase 2Volontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 mag 2025 · NCT06049355

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

  • VA Portland Healthcare System, Portland
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 20 apr 2022 · NCT03753243

Fonte: ClinicalTrials.gov, dati recuperati il 4 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.